

PD-1 Resistant Head and Neck Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Cytotoxic Agents, EGFR Inhibitors, PD-1 Inhibitors, Pipeline Drugs), By End User (Hospitals, Clinics, Others), By Region, By Competition

Market Report | 2023-11-07 | 182 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4900.00
- Multi-User License \$5900.00
- Custom Research License \$8900.00

Report description:

Global PD-1 Resistant Head and Neck Cancer Market has valued at USD 1.19 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 9.45% through 2028. PD-1 resistance is a common problem in head and neck cancer, and it has led to a significant gap in treatment options. PD-1 is a protein that is found on the surface of T cells, which are a type of immune cell that plays a key role in fighting off infections and cancer. The market for PD-1-resistant head and neck cancer is a rapidly growing field with significant unmet medical needs. The market is driven by the high incidence of head and neck cancer, the need for effective treatment options for patients who are resistant to current therapies, and the growing interest in immunotherapy as a treatment approach. The PD-1 Resistant Head and Neck Cancer (HNC) Market is expected to grow at a steady rate of around 13% owing to the increasing prevalence of cancer among the population. For instance, Head and neck cancer is the seventh most common cancer in the world, with 1.1 million new diagnoses reported each year.

Key Market Drivers

Advancements in Immunotherapy Research

The relentless pursuit of advancements in immunotherapy research is poised to catalyze substantial growth in the global PD-1 resistant head and neck cancer market. Immunotherapy, specifically targeting programmed cell death protein 1 (PD-1), has emerged as a groundbreaking approach in cancer treatment. As researchers delve deeper into understanding the complexities of PD-1 resistant head and neck cancer, innovative solutions are anticipated to evolve, driving market expansion. The development of novel immunotherapeutic agents capable of overcoming PD-1 resistance presents a compelling business prospect. Companies at the forefront of this research are likely to gain a competitive edge, offering enhanced treatment options for patients facing limited alternatives. Moreover, as the therapeutic landscape evolves, collaborations and strategic partnerships may become

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

instrumental, fostering accelerated research and development. In this dynamic market environment, firms positioned to capitalize on breakthroughs in immunotherapy stand to benefit from increased market share and revenue growth. The intersection of scientific progress and market opportunities in PD-1 resistant head and neck cancer underscores the transformative potential of ongoing immunotherapy research in reshaping the business landscape within the healthcare sector.

Increased Incidence Rates

The surge in incidence rates is set to propel the growth of the global PD-1 resistant head and neck cancer market. As the prevalence of PD-1 resistant cases escalates, there is a corresponding increase in the demand for advanced and effective treatment options. This upswing in patient numbers not only represents a significant public health concern but also translates into a substantial business opportunity for pharmaceutical and biotechnology companies operating in the oncology space. The growing patient pool intensifies the need for innovative therapies specifically tailored to address PD-1 resistant head and neck cancer, fostering a lucrative market environment. Companies investing in research and development to meet this demand are positioned to capitalize on the expanding market, offering solutions that cater to the rising patient population. The economic implications of this trend extend beyond healthcare, creating a robust market ecosystem that incentivizes companies to invest in cutting-edge technologies and therapies, thereby driving sustained growth in the global PD-1 resistant head and neck cancer market.

Growing Awareness and Education

The growth of the global PD-1 resistant head and neck cancer market is poised to be significantly influenced by the increasing awareness and education surrounding this critical health issue. As awareness spreads among healthcare professionals, patients, and the general public, there is a heightened recognition of the complexities associated with PD-1 resistant head and neck cancer. This heightened understanding fosters early detection, diagnosis, and proactive management strategies. Moreover, growing awareness empowers stakeholders to make informed decisions about treatment options, creating a demand for cutting-edge therapies within the market. Patients, guided by a more comprehensive understanding of PD-1 resistance, may seek advanced interventions, driving market expansion. Furthermore, heightened awareness often translates into increased funding for research and development initiatives, spurring innovation within the pharmaceutical and biotechnology sectors. Educational efforts also play a pivotal role in shaping healthcare policies, encouraging collaborations, and reducing the stigma associated with the disease. As the global community becomes more informed, a favorable environment for market growth emerges, offering opportunities for businesses to meet the evolving needs of a discerning and educated market. In essence, the symbiotic relationship between awareness, education, and market growth underscores the significance of informed decision-making in the realm of PD-1 resistant head and neck cancer.

Key Market Challenges

Limited Treatment Options

The growth trajectory of the global PD-1 resistant head and neck cancer market faces a formidable impediment in the form of limited treatment options. The scarcity of effective therapies for PD-1 resistant cases restricts the ability of healthcare providers to address the complex needs of patients, hindering market expansion. This dearth of treatment alternatives not only poses a significant challenge to patient care but also diminishes the overall market potential for pharmaceutical and biotechnology companies. The constrained treatment landscape diminishes competitive dynamics within the market, limiting innovation and the emergence of new entrants. Additionally, it curtails the ability of existing players to capture a larger market share and leverage competitive advantages. Investors and stakeholders, cognizant of the constrained treatment options, may exhibit hesitancy in committing resources to the development of therapies for PD-1 resistant head and neck cancer. Addressing this limitation necessitates heightened research and development efforts to diversify treatment modalities. Overcoming the hurdle of limited options is essential for fostering market growth, as breakthrough innovations will not only meet the unmet medical needs of patients but also unlock substantial business opportunities in a market characterized by heightened demand for effective solutions.

Complexity of Tumor Biology

The complexity of tumor biology stands as a significant impediment to the growth of the global PD-1 resistant head and neck cancer market. The intricate and multifaceted nature of tumor biology poses formidable challenges in developing targeted therapies that effectively combat PD-1 resistance. This complexity introduces uncertainties in understanding the molecular mechanisms underlying resistance, impeding the timely development of innovative treatment strategies. As researchers grapple

with the intricacies of tumor biology, the pace of drug discovery and development is inevitably slowed. The need for precision in addressing diverse genetic mutations and signaling pathways adds layers of complexity, demanding substantial investments in research and development. Consequently, the prolonged timeline for bringing new therapies to market hinders the market's ability to meet the urgent needs of patients facing PD-1 resistant head and neck cancer. Moreover, the intricate tumor biology complicates clinical trial designs, making it challenging to identify suitable patient cohorts and endpoints. This complexity not only increases development costs but also raises the risk of trial failures. Overcoming these challenges requires sustained investment, collaboration, and innovative approaches to unravel the complexities of tumor biology, ultimately unlocking the growth potential of the PD-1 resistant head and neck cancer market.

Key Market Trends

Advancements in Combination Therapies

The growth of the global PD-1 resistant head and neck cancer market is poised for acceleration through advancements in combination therapies. As researchers delve into innovative approaches, the development of combination therapies emerges as a promising strategy to overcome resistance challenges. Combining PD-1 inhibitors with other targeted agents or immunomodulators has the potential to enhance treatment efficacy by addressing the multifaceted nature of resistance mechanisms. These advancements not only signify a paradigm shift in the therapeutic landscape but also present a compelling business opportunity. Companies investing in the research and development of synergistic combination therapies position themselves at the forefront of market innovation. The strategic combination of different therapeutic modalities not only increases the chances of treatment success but also fosters a competitive edge in the dynamic oncology market. Furthermore, the emergence of effective combination therapies is likely to expand the addressable patient population, driving market growth. This trend underscores the pivotal role of collaboration, research, and strategic partnerships in navigating the complexities of PD-1 resistant head and neck cancer, ultimately propelling the market forward into a new era of more effective and comprehensive treatment options.

Personalized Medicine and Biomarker Development

The growth of the global PD-1 resistant head and neck cancer market is poised to be significantly influenced by the advent of personalized medicine and biomarker development. Personalized medicine, tailoring treatment based on individual patient characteristics, holds immense potential in addressing the intricacies of PD-1 resistance. As biomarkers associated with resistance mechanisms are identified and validated, a more precise and targeted therapeutic approach becomes possible. This paradigm shift towards personalized medicine not only enhances treatment efficacy but also represents a strategic business opportunity. Companies investing in biomarker-driven research and development can position themselves at the forefront of innovation, offering tailored solutions that cater to the specific needs of patients with PD-1 resistant head and neck cancer. The ability to identify patient subgroups through biomarkers not only aids in treatment selection but also streamlines clinical trial designs, potentially accelerating the drug development process. The integration of personalized medicine and biomarker development is expected to reshape the market dynamics, fostering a more patient-centric and efficient approach to addressing PD-1 resistance. The evolving landscape underscores the significance of strategic investments and collaborations in driving advancements that will define the future of the global PD-1 resistant head and neck cancer market.

Segmental Insights

Product Insights

Based on the Product, the Cytotoxic Agents segment is anticipated to witness substantial market growth throughout the forecast period. The growth of the global PD-1 resistant head and neck cancer market is set to be catalyzed by the strategic integration of cytotoxic agents. Cytotoxic therapies, with their ability to induce cell death, offer a complementary approach to immune checkpoint inhibitors like PD-1 inhibitors. Combining cytotoxic agents with PD-1 inhibitors represents a synergistic strategy to address the resistant nature of certain tumors, enhancing the overall treatment efficacy. This integration presents a compelling business opportunity for pharmaceutical companies as it diversifies the therapeutic arsenal, providing more comprehensive solutions for patients with PD-1 resistant head and neck cancer. The potential for combination therapies to deliver improved clinical outcomes positions such interventions favorably in the competitive landscape. Companies investing in the research and development of cytotoxic agents, both as standalone treatments and in combination regimens, are poised to play a pivotal role in shaping the market's trajectory. Moreover, the incorporation of cytotoxic agents into treatment protocols not only expands the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

therapeutic options but also contributes to addressing the heterogeneity of resistant tumors. This strategic evolution underscores the dynamic nature of the market and highlights the potential for innovative cytotoxic approaches to drive substantial growth in the global PD-1 resistant head and neck cancer market.

End User Insights

Based on the End User segment, the Hospitals segment has been the dominant force in the market. Hospitals are poised to play a pivotal role in driving the growth of the global PD-1 resistant head and neck cancer market. The increasing prevalence of PD-1 resistant cases underscores the critical need for advanced treatment options, prompting hospitals to invest in state-of-the-art technologies and therapeutic approaches. Hospitals, as key stakeholders in patient care, will likely become central hubs for the adoption and implementation of cutting-edge therapies targeting PD-1 resistant head and neck cancer. The growth of the market is intricately tied to the infrastructure and capabilities of hospitals to offer these innovative treatments. Hospitals that prioritize the incorporation of such advanced therapies into their oncology departments not only enhance patient outcomes but also position themselves as leaders in the competitive healthcare landscape. The adoption of novel treatments within hospital settings creates a collaborative ecosystem, attracting skilled medical professionals, researchers, and pharmaceutical partnerships. Furthermore, hospitals serve as focal points for clinical trials and research initiatives, contributing valuable data to refine and expand treatment options. As hospitals actively engage in addressing the challenges of PD-1 resistance, they become catalysts for market growth by fostering an environment that encourages the development, accessibility, and integration of groundbreaking therapies in the global fight against PD-1 resistant head and neck cancer.

Regional Insights

North America, specifically the PD-1 Resistant Head and Neck Cancer Market, dominated the market in 2022, primarily due to North America is positioned as a driving force in propelling the growth of the global PD-1 resistant head and neck cancer market. The region's leadership in healthcare infrastructure, advanced research capabilities, and a robust pharmaceutical industry positions it as a key player in addressing the challenges posed by PD-1 resistance. Major pharmaceutical companies headquartered in North America are at the forefront of research and development efforts, investing substantially in innovative therapies and targeted solutions for PD-1 resistant head and neck cancer. The region's healthcare ecosystem, characterized by a high level of awareness and well-established regulatory frameworks, facilitates the swift adoption of novel treatments. Additionally, the prevalence of collaborative initiatives between academic institutions, research organizations, and pharmaceutical companies fosters an environment conducive to breakthrough discoveries. North America's significant patient population, coupled with a well-developed healthcare reimbursement system, further contributes to the market's growth by providing a robust foundation for the commercialization of advanced therapies. Furthermore, the proactive engagement of healthcare professionals and the availability of cutting-edge medical technologies position North America as a key market influencer, contributing to the development and successful implementation of next-generation therapies for PD-1 resistant head and neck cancer on a global scale.

Key Market Players

Ayala Pharmaceuticals D srl.

Amgen Inc.

AstraZeneca plc.

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

Cel-Sci

GSK plc

Incyte

Merck KGaA

Novartis AG.

Report Scope:

In this report, the Global PD-1 Resistant Head and Neck Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

PD-1 Resistant Head and Neck Cancer Market, By Product:

- Cytotoxic Agents
- EGFR Inhibitors
- PD-1 Inhibitors
- Pipeline Drugs

PD-1 Resistant Head and Neck Cancer Market, By End-User:

- Hospitals
- Clinics
- Others

PD-1 Resistant Head and Neck Cancer Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Turkey

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global PD-1 Resistant Head and Neck Cancer Market.

Available Customizations:

Global PD-1 Resistant Head and Neck Cancer market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.1.□Market Definition
- 1.2.□Scope of the Market
 - 1.2.1.□Markets Covered
 - 1.2.2.□Years Considered for Study
 - 1.2.3.□Key Market Segmentations
- 2.□Research Methodology
 - 2.1.□Objective of the Study
 - 2.2.□Baseline Methodology
 - 2.3.□Key Industry Partners
 - 2.4.□Major Association and Secondary Sources
 - 2.5.□Forecasting Methodology
 - 2.6.□Data Triangulation & Validation
 - 2.7.□Assumptions and Limitations
- 3.□Executive Summary
 - 3.1.□Overview of the Market
 - 3.2.□Overview of Key Market Segmentations
 - 3.3.□Overview of Key Market Players
 - 3.4.□Overview of Key Regions/Countries
 - 3.5.□Overview of Market Drivers, Challenges, Trends
- 4.□Voice of Customer
- 5.□Global PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 5.1.□Market Size & Forecast
 - 5.1.1.□By Value
 - 5.2.□Market Share & Forecast
 - 5.2.1.□By Product (Cytotoxic Agents, EGFR Inhibitors, PD-1 Inhibitors, Pipeline Drugs)
 - 5.2.2.□By End User (Hospitals, Clinics, Others)
 - 5.2.3.□By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
 - 5.2.4.□By Company (2022)
 - 5.3.□Market Map
 - 5.3.1 By Type
 - 5.3.2 By End User
 - 5.3.3 By Region
- 6.□North America PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 6.1.□Market Size & Forecast□
 - 6.1.1.□By Value
 - 6.2.□Market Share & Forecast
 - 6.2.1.□By Product (Cytotoxic Agents, EGFR Inhibitors, PD-1 Inhibitors, Pipeline Drugs)
 - 6.2.2.□By End User (Hospitals, Clinics, Others)
 - 6.2.3.□By Country
 - 6.3.□North America: Country Analysis
 - 6.3.1.□United States PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 6.3.1.1.□Market Size & Forecast
 - 6.3.1.1.1.□By Value
 - 6.3.1.2.□Market Share & Forecast
 - 6.3.1.2.1.□By Type
 - 6.3.1.2.2.□By End User
 - 6.3.2.□Canada PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.2.1.□Market Size & Forecast
 - 6.3.2.1.1.□By Value
- 6.3.2.2.□Market Share & Forecast
 - 6.3.2.2.1.□By Type
 - 6.3.2.2.2.□By End User
- 6.3.3.□Mexico PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 6.3.3.1.□Market Size & Forecast
 - 6.3.3.1.1.□By Value
 - 6.3.3.2.□Market Share & Forecast
 - 6.3.3.2.1.□By Type
 - 6.3.3.2.2.□By End User
- 7.□Europe PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 7.1.□Market Size & Forecast□
 - 7.1.1.□By Value
 - 7.2.□Market Share & Forecast
 - 7.2.1.□By Product (Cytotoxic Agents, EGFR Inhibitors, PD-1 Inhibitors, Pipeline Drugs)
 - 7.2.2.□By End User (Hospitals, Clinics, Others)
 - 7.2.3.□By Country
 - 7.3.□Europe: Country Analysis
 - 7.3.1.□France PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 7.3.1.1.□Market Size & Forecast
 - 7.3.1.1.1.□By Value
 - 7.3.1.2.□Market Share & Forecast
 - 7.3.1.2.1.□By Type
 - 7.3.1.2.2.□By End User
 - 7.3.2.□Germany PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 7.3.2.1.□Market Size & Forecast
 - 7.3.2.1.1.□By Value
 - 7.3.2.2.□Market Share & Forecast
 - 7.3.2.2.1.□By Type
 - 7.3.2.2.2.□By End User
 - 7.3.3.□United Kingdom PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 7.3.3.1.□Market Size & Forecast
 - 7.3.3.1.1.□By Value
 - 7.3.3.2.□Market Share & Forecast
 - 7.3.3.2.1.□By Type
 - 7.3.3.2.2.□By End User
 - 7.3.4.□Italy PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 7.3.4.1.□Market Size & Forecast
 - 7.3.4.1.1.□By Value
 - 7.3.4.2.□Market Share & Forecast
 - 7.3.4.2.1.□By Type
 - 7.3.4.2.2.□By End User
 - 7.3.5.□Spain PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 7.3.5.1.□Market Size & Forecast
 - 7.3.5.1.1.□By Value
 - 7.3.5.2.□Market Share & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.5.2.1. By Type
- 7.3.5.2.2. By End User
- 8. Asia-Pacific PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Product (Cytotoxic Agents, EGFR Inhibitors, PD-1 Inhibitors, Pipeline Drugs)
 - 8.2.2. By End User (Hospitals, Clinics, Others)
 - 8.2.3. By Country
 - 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Type
 - 8.3.1.2.2. By End User
 - 8.3.2. India PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Type
 - 8.3.2.2.2. By End User
 - 8.3.3. Japan PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Type
 - 8.3.3.2.2. By End User
 - 8.3.4. South Korea PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast
 - 8.3.4.2.1. By Type
 - 8.3.4.2.2. By End User
 - 8.3.5. Australia PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value
 - 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Type
 - 8.3.5.2.2. By End User
 - 9. South America PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Product (Cytotoxic Agents, EGFR Inhibitors, PD-1 Inhibitors, Pipeline Drugs)
 - 9.2.2. By End User (Hospitals, Clinics, Others)
 - 9.2.3. By Country

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3. South America: Country Analysis
 - 9.3.1. Brazil PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Type
 - 9.3.1.2.2. By End User
 - 9.3.2. Argentina PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Type
 - 9.3.2.2.2. By End User
 - 9.3.3. Colombia PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Type
 - 9.3.3.2.2. By End User
- 10. Middle East and Africa PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 10.1. Market Size & Forecast
 - 10.1.1. By Value
 - 10.2. Market Share & Forecast
 - 10.2.1. By Product (Cytotoxic Agents, EGFR Inhibitors, PD-1 Inhibitors, Pipeline Drugs)
 - 10.2.2. By End User (Hospitals, Clinics, Others)
 - 10.2.3. By Country
 - 10.3. MEA: Country Analysis
 - 10.3.1. South Africa PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Type
 - 10.3.1.2.2. By End User
 - 10.3.2. Saudi Arabia PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Type
 - 10.3.2.2.2. By End User
 - 10.3.3. UAE PD-1 RESISTANT HEAD AND NECK CANCER Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Type
 - 10.3.3.2.2. By End User
- 11. Market Dynamics
 - 11.1. Drivers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2.□Challenges
- 12.□Market Trends & Developments
- 12.1.□Recent Development
- 12.2.□Mergers & Acquisitions
- 12.3.□Product Launches
- 13.□Global PD-1 RESISTANT HEAD AND NECK CANCER Market: SWOT Analysis
- 14.□Porter's Five Forces Analysis
- 14.1.□Competition in the Industry
- 14.2.□Potential of New Entrants
- 14.3.□Power of Suppliers
- 14.4.□Power of Customers
- 14.5.□Threat of Substitute Products
- 15.□Competitive Landscape
- 15.1.□Ayala Pharmaceuticals.
- 15.1.1.□Business Overview
- 15.1.2.□Product Offerings
- 15.1.3.□Recent Developments
- 15.1.4.□Financials (As Reported)
- 15.1.5.□Key Personnel
- 15.1.6.□SWOT Analysis
- 15.2.□Amgen Inc.
- 15.3.□AstraZeneca plc.
- 15.4.□Boehringer Ingelheim International GmbH
- 15.5.□Bristol-Myers Squibb Company
- 15.6.□Cel-Sci
- 15.7.□GSK plc
- 15.8.□Incyte
- 15.9.□Merck KGaA
- 15.10.□Novartis AG.
- 16.□Strategic Recommendations

PD-1 Resistant Head and Neck Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Cytotoxic Agents, EGFR Inhibitors, PD-1 Inhibitors, Pipeline Drugs), By End User (Hospitals, Clinics, Others), By Region, By Competition

Market Report | 2023-11-07 | 182 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4900.00
	Multi-User License	\$5900.00
	Custom Research License	\$8900.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-06-22

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com